Drugs associated with restless legs syndrome: A case/noncase study in the French pharmacovigilance database

Journal of Clinical Psychopharmacology

Volumn 32, Issue 6, 2012, Pages 824-827

  Perez Lloret, Santiago ^a,b   Rey, María Verónica ^a,b   Bondon Guitton, Emmanuelle ^a,c   Rascol, Olivier ^a,b   Montastruc, And Jean Louis ^a,c  

^a Ctr Midi Pyrenees Pharmacovigilance Pharmacoepidemiologie Informations Medicament   (Argentina)

^b CNRS   (France)

^c INSERM   (France)

Author keywords

adverse drug reactions; drug induced movement disorders; pharmacovigilance; restless legs syndrome; sleep related movement disorders

Indexed keywords

ALANINE; AMITRIPTYLINE; ARIPIPRAZOLE; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; DOCETAXEL; DULOXETINE; ESCITALOPRAM; FOSFOMYCIN; LEUPRORELIN; LOXAPINE; MIANSERIN; MIRTAZAPINE; MORPHINE; NICERGOLINE; NITROFURANTOIN; ORNITHINE; OXYBATE SODIUM; RISPERIDONE; ROPINIROLE; THIORIDAZINE; TRAMADOL; TRIMETAZIDINE; VALPROMIDE;

ADULT; AGED; CLINICAL ARTICLE; DATA BASE; DRUG SURVEILLANCE PROGRAM; FEMALE; FRANCE; HUMAN; MALE; MORBIDITY; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; REVIEW;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DATABASES, FACTUAL; DRUG TOXICITY; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; PHARMACOVIGILANCE; RESTLESS LEGS SYNDROME; TRAMADOL; YOUNG ADULT;

EID: 84870242404     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318272cdd8     Document Type: Review

References (27)

1. Ekbom K, Ulfberg J. Restless legs syndrome. J Intern Med. 2009;266:419-431.
2. Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome. Lancet Neurol. 2005;4:465-475. (Pubitemid 40982457)
3. Hoque R, Chesson AL Jr. Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: Literature review, qualitative scoring, and comparative analysis. J Clin Sleep Med. 2010;6:79-83.
4. Montastruc JL, Sommet A, Lacroix I, et al. Pharmacovigilance for evaluating adverse drug reactions: Value, organization, and methods. Joint Bone Spine. 2006;73:629-632. (Pubitemid 44932244)
5. Begaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie. 1985;40:111-118.
6. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet. 2000;356:1255-1259.
7. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101-119. (Pubitemid 36527231)
8. Egberts AC, Meyboom RH, van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: Three Dutch examples. Drug Saf. 2002;25:453-458. (Pubitemid 34729145)
9. Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: A case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol. 1997;44:513-518. (Pubitemid 27485484)
10. Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol. 2004;57: 127-134. (Pubitemid 38223524)
11. Olivier P, Montastruc JL. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. Pharmacoepidemiol Drug Saf. 2006;15:808-812. (Pubitemid 44767097)
12. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: A systematic review. Drug Saf. 2006;29:385-396.
13. Begaud B, Martin K, Haramburu F, et al. Rates of spontaneous reporting of adverse drug reactions in France. JAMA. 2002;288:1588.
14. Tavassoli N, Lapeyre-Mestre M, Sommet A, et al. Reporting rate of adverse drug reactions to the French pharmacovigilance system with three step 2 analgesic drugs: Dextropropoxyphene, tramadol and codeine (in combination with paracetamol). Br J Clin Pharmacol 2009;68:422-426.
15. Montastruc G, Favreliere S, Sommet A, et al. Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database. Br J Clin Pharmacol. 2010;69: 287-294.
16. Montastruc JL, Sommet A, Bagheri H, et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a PharmacoVigilance database. Br J Clin Pharmacol. 2011;72(6):905-908.
17. Myers BA, Klerman GL, Hartmann E. Nocturnal cataclysms with myoclonus: A new side effect of clomipramine. Am J Psychiatry. 1986;143:1490-1491.
18. Paik IH, Lee C, Choi BM, et al. Mianserin-induced restless legs syndrome. Br J Psychiatry. 1989;155:415-417. (Pubitemid 19237023)
19. Agargun MY, Kara H, Ozbek H, et al. Restless legs syndrome induced by mirtazapine. J Clin Psychiatry. 2002;63:1179. (Pubitemid 36084064)
20. Rottach KG, Schaner BM, Kirch MH, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res. 2008;43:70-75.
21. Horiguchi J, Yamashita H, Mizuno S, et al. Nocturnal eating/drinking syndrome and neuroleptic-induced restless legs syndrome. Int Clin Psychopharmacol. 1999;14:33-36. (Pubitemid 29054591)
22. Kraus T, Schuld A, Pollmacher T. Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine. J Clin Psychopharmacol. 1999;19:478-479. (Pubitemid 29451517)
23. Wetter TC, Brunner J, Bronisch T. Restless legs syndrome probably induced by risperidone treatment. Pharmacopsychiatry. 2002;35: 109-111. (Pubitemid 34651917)
24. Earley CJ, Allen RP. Restless legs syndrome augmentation associated with tramadol. Sleep Med. 2006;7:592-593. (Pubitemid 44488097)
25. Vetrugno R, La MC, D'Angelo R, et al. Augmentation of restless legs syndrome with long-term tramadol treatment. Mov Disord. 2007;22: 424-427. (Pubitemid 46569705)
26. Kim SW, Shin IS, Kim JM, et al. Factors potentiating the risk of mirtazapine-associated restless legs syndrome. Hum Psychopharmacol. 2008;23:615-620.
27. Montastruc JL, Sommet A, Olivier P, et al. Drugs, Parkinson's disease and parkinsonian syndrome: Recent advances in pharmacovigilance. Therapie. 2006;61:29-38. (Pubitemid 350213993)